Impact of Probiotic Supplementation on Cognition and Related Health Outcomes Among Video Gamers
Impact of Probiotic Supplementation on Cognition and Related Health Outcomes Among Video Gamers: A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Participants who are action gamers will be recruited to participate in this randomized, placebo-controlled, 2-arm, parallel trial. Eligible participants will be enrolled in this study for 8 weeks.
The study will consist of 2 laboratory visits: Baseline Visit and Post-Treatment Visit.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Cory Munroe, Ph.D. candidate
- Phone Number: (902)-574-4567
- Email: cory.munroe@dal.ca
Study Contact Backup
- Name: Sara E Caballero Calero, M.Sc
- Phone Number: 514-283-1387
- Email: scaballero@lallemand.com
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H4R2
- Cognitive and Motor Performance Lab, Dalplex, Kinesiology Suites, Dalhousie University (Rm. 213)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female adults aged 19 to 35 years-old.
- Have played action video games (i.e., first- and third-person shooter and action role playing games) for a minimum of 5 hours per week over the course of the previous year as assessed by self-report (as per [1])
- Willingness to continue the same amount of video game playing throughout the duration of the study.
- Willingness to maintain eating habits throughout the duration of the study.
- Willingness to discontinue consumption of probiotic supplements and probiotic- fortified products, as well as fiber supplement consumption (e.g., Metamucil, Benefiber, etc.), throughout the duration of the study.
- Willingness to maintain current physical activity levels throughout the duration of the study.
- Willing and able to consume a probiotic or placebo supplement for 8 weeks.
- Willingness to complete questionnaires, records, and diaries associated with the study and to complete all study visits.
- Able to provide informed consent.
Exclusion Criteria:
- Use of antidepressants, anti-anxiolytic medication, and/or medication that improves attention, including amphetamines, methylphenidates, dexmethylphenidates, and atomoxetine hydrochloride.
- Disordered gaming, as per a score above 32 on the Internet Gaming Disorder Scale Short Form (IGDS9-SF; [2]).
- Head trauma that was diagnosed by a medical professional as a concussion or was associated with a loss of consciousness within the past two years.
- Currently diagnosed with alcohol use disorder and/or substance use disorder.
- Diabetes (type I and II), blood/bleeding disorders, liver and/or kidney disorders, unstable cardiovascular diseases, neurological diseases (e.g., Alzheimer's disease, Parkinson's disease, epilepsy), gastrointestinal diseases (e.g., gastric ulcers, Crohn's disease, ulcerative colitis).
- Presence of unrelated sleep disorders, diagnosis of a mental disorder within the previous year, history of diagnosis of attention-deficit/hyperactivity disorder or attention-deficit disorder
- Immunodeficiency (immune-compromised and immune-suppressed participants; e.g., AIDS, lymphoma, participants undergoing long-term corticosteroid treatment, chemotherapy and allograft participants).
- Arthritis pain or other chronic pain.
- Currently suffering from periodontitis.
- Pregnancy (as per urine pregnancy test at screening), planning to be pregnant or currently breastfeeding.
- Females of childbearing potential not using a medically approved method of birth control (e.g. hormonal contraception, intrauterine devices, vasectomy/tubal ligation, barrier methods, double-barrier method) or true abstinence.
- Milk, soy, and/or yeast allergy.
- Lactose intolerance.
- Use of any antibiotic drug within 4 weeks of randomization. Volunteer could be eligible to participate after a 2-week washout period.
- Current use of probiotics. Volunteer can be eligible after a four (4)-week washout period.
- Currently enrolled in another clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Probiotic
Participants will be randomized to receive the probiotic formulation for 8 weeks.
|
Participants will be asked to take 1 capsule (3 billion CFU) daily for 8 weeks in the morning with their first meal.
|
|
Placebo Comparator: Placebo
Participants will be randomized to receive the placebo formulation for 8 weeks.
|
Participants will be asked to take 1 capsule daily for 8 weeks in the morning with their first meal.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in reaction time
Time Frame: 8 weeks
|
The statistical difference in change in reaction time (in milliseconds) from baseline during a computerized task-switching color-word Stroop task following acute stress between the probiotic and placebo groups.
|
8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in reaction time: acute stress condition
Time Frame: 8 weeks
|
The statistical difference in changes in reaction time (in milliseconds) on a computerized incongruent CWST between probiotic and placebo groups following acute stress.
|
8 weeks
|
|
Change in accuracy: acute stress condition
Time Frame: 8 weeks
|
The statistical difference in changes in accuracy (proportion correct) on a computerized task-switching CWST and incongruent CWST between probiotic and placebo groups following acute stress.
|
8 weeks
|
|
Change in reaction time: non-stressful condition
Time Frame: 8 weeks
|
The statistical difference in changes in reaction time (in milliseconds) on a computerized task-switching and incongruent CWST and a visual search (VS) paradigm, between probiotic and placebo groups in a non-stressful condition.
|
8 weeks
|
|
Change in accuracy: non-stressful condition
Time Frame: 8 weeks
|
The statistical difference in changes in accuracy (proportion correct; %false alarms) on a computerized task-switching and an incongruent CWST, a go/no-go paradigm, a visual working memory maintenance paradigm, and a visual working memory complex span task (SYMSPAN) between probiotic and placebo groups in a non-stressful condition.
|
8 weeks
|
|
Change in self-reported cognitive control: non-stressful condition
Time Frame: 8 weeks
|
The statistical difference in changes in self-reported cognitive control and cognitive flexibility as per the Cognitive Control and Flexibility Questionnaire (CCFQ) between probiotic and placebo groups in a non-stressful condition.
|
8 weeks
|
|
Changes in oxyhemoglobin concentrations in pre-frontal cortex
Time Frame: 8 weeks
|
The statistical difference in changes in concentrations of oxygenated hemoglobin in the prefrontal cortex (PFC) during the task-switching CWST from baseline between the probiotic and placebo groups following acute stress and under non-stress conditions.
|
8 weeks
|
|
Changes in cortisol
Time Frame: 8 weeks
|
The statistical difference in changes in the cortisol response to acute stress from baseline, as measured by the area under the curve with respect to increase (AUCi) and with respect to ground (AUCg) between probiotic and placebo groups.
|
8 weeks
|
|
Changes in salivary DHEA-S
Time Frame: 8 weeks
|
The statistical difference in salivary DHEA-S from baseline between the probiotic and placebo groups.
|
8 weeks
|
|
Changes in salivary cortisol/DHEA-S ratio
Time Frame: 8 weeks
|
The statistical difference in the salivary cortisol/DHEA-S ratio from baseline between the probiotic and placebo groups.
|
8 weeks
|
|
Changes in immune activity markers
Time Frame: 8 weeks
|
The statistical difference in changes in salivary levels of proinflammatory cytokines, interleukin-1 beta, and interleukin-6 from baseline between probiotic and placebo groups.
|
8 weeks
|
|
Changes in self-reported levels of depression symptomology
Time Frame: 8 weeks
|
The statistical difference in changes in the depression subscale score of the Depression, Anxiety, and Stress Scale Short Form (DASS-21) from baseline between the probiotic and placebo groups.
|
8 weeks
|
|
Changes in self-reported levels of anxiety symptomology
Time Frame: 8 weeks
|
The statistical difference in changes in the anxiety subscale score of the Depression, Anxiety, and Stress Scale Short Form (DASS-21) from baseline between the probiotic and placebo groups.
|
8 weeks
|
|
Changes in self-reported levels of perceived stress symptomology
Time Frame: 8 weeks
|
The statistical difference in changes in the stress subscale score of the Depression, Anxiety, and Stress Scale Short Form (DASS-21) from baseline between the probiotic and placebo groups.
|
8 weeks
|
|
Changes in self-reported levels of anxiety, depression, and perceived stress symptomology
Time Frame: 8 weeks
|
The statistical difference in changes in the total scale score of the Depression, Anxiety, and Stress Scale Short Form (DASS-21) between the probiotic and placebo groups.
|
8 weeks
|
|
Changes in self-reported sleep quality
Time Frame: 8 weeks
|
The statistical differences in changes in total Pittsburgh Sleep Quality Index (PSQI) scores between the probiotic and placebo groups.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Tara Perrot, Ph.D., Dalhousie University
- Principal Investigator: Heather Neyedli, Ph.D., Dalhousie University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- L-025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.